Clarivate CLVT 深 沪
已收盘 11-06 16:00:00 美东时间
2.34
+0.010
+0.43%
华盛通- 最 高2.405
- 今 开2.27
- 成交量 468.63万股
- 最 低 2.24
- 昨 收 2.33
- 总市值 14.97亿
- 52周最高 3.87
- 市盈率 静 --
- 换手率 0.73%
- 52周最低 1.42
- 委 比 -59.84%
- 总股本 6.40亿
- 历史最高 34.79
- 量 比 0.66
- 振 幅 7.08%
- 历史最低 1.42
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 可口可乐、麦当劳、3M等获多家大行看好；机构上调高通目标价至165美元
今日重点评级关注：Citizens：维持Precigen"跑赢大市"评级，目标价从11美元升至12美元；Leerink Partners：维持Arcus Biosciences"跑赢大市"评级，目标价从46美元升至49美元
11-06 16:15
Goldman Sachs Maintains Neutral on Clarivate, Lowers Price Target to $2.3
Goldman Sachs analyst George Tong maintains Clarivate (NYSE:CLVT) with a Neutral and lowers the price target from $2.6 to $2.3.
11-06 01:57
Clarivate Announces Tender Offers for Senior Notes
Clarivate ( ($CLVT) ) has issued an announcement. On November 4, 2026, Clarivat...
11-04 22:49
Clarivate shares are trading higher after the company reported better-than-expected Q3 financial results.
Clarivate shares are trading higher after the company reported better-than-expected Q3 financial results.
11-04 00:00
财报速睇 | Clarivate 2026财年Q3营收4.82亿美元，同比下降9.2%；归母净利润亏损0.81亿美元，同比亏损扩大185.5%
华盛资讯11月3日讯，Clarivate公布2026财年Q3业绩，公司Q3营收4.82亿美元，同比下降9.2%，归母净利润亏损0.81亿美元，同比亏损扩大185.5%。
11-03 23:07
Clarivate Reports Third-Quarter Results Amid Revenue Decline
Clarivate ( ($CLVT) ) has provided an announcement. On November 3, 2026, Clariv...
11-03 21:56
Clarivate Sees Q4 Adj EPS $0.14-$0.18 vs $0.19 Est; Sees Sales $490.000M-$510.000M vs $562.824M Est
Clarivate (NYSE:CLVT) is looking for Q4 Adj EPS of $0.14-$0.18 vs $0.19 analyst estimate. sees sales of $490.000 million-$510.000 million vs $562.824 million analyst estimate.
11-03 19:09
Clarivate To Roll Out CompuMark Trademark Data Into Microsoft Copilot
Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced it will bring trusted CompuMark trademark data and insights into Microsoft Copilot through IPOne, enabling intellectual property (IP) professionals to put authoritative trademark intelligence to work...
11-02 20:53
Clarivate (CLVT) Receives a Sell from Morgan Stanley
Morgan Stanley analyst Toni Kaplan initiated coverage with a Sell rating on Cla...
10-30 19:59
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED announces FDA grants Orphan Drug Designation to sovleplenib for treating primary immune thrombocytopenia (ITP), a rare autoimmune disorder. Sovleplenib, a novel Syk inhibitor, addresses significant unmet needs in ITP patients. The designation offers 7 years of US market exclusivity and other development incentives. HUTCHMED retains global rights to sovleplenib, with NDAs under review in China supported by positive trial data. ITP affects...
10-29 00:00
